Salarius Pharmaceuticals Inc [NASDAQ: SLRX] traded at a high on 2025-11-26, posting a 4.79 gain after which it closed the day’ session at $0.93.
The results of the trading session contributed to over 330113 shares changing hands. Over the past one week, the price volatility of Salarius Pharmaceuticals Inc stands at 11.82% while the volatility over the past one month is 19.28%.
The market cap for SLRX stock reached $5.42 million, with 5.86 million shares outstanding and 5.51 million shares in the current float. Compared to the average trading volume of 1.77M shares, SLRX reached a trading volume of 330113 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Salarius Pharmaceuticals Inc [SLRX]?
Ladenburg Thalmann have made an estimate for Salarius Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 27, 2020.
The Price to Book ratio for the last quarter was 0.21, with the Price to Cash per share for the same quarter was set at 0.82.
How has SLRX stock performed recently?
Salarius Pharmaceuticals Inc [SLRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.73. With this latest performance, SLRX shares dropped by -75.17% in over the last four-week period, additionally sinking by -92.19% over the last 6 months – not to mention a drop of -96.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLRX stock in for the last two-week period is set at 25.06, with the RSI for the last a single of trading hit 0.2659, and the three-weeks RSI is set at 0.3873 for Salarius Pharmaceuticals Inc [SLRX]. The present Moving Average for the last 50 days of trading for this stock 3.1503, while it was recorded at 0.8745 for the last single week of trading, and 9.4403 for the last 200 days.
Salarius Pharmaceuticals Inc (SLRX) Capital Structure & Debt Analysis
According to recent financial data for Salarius Pharmaceuticals Inc. ( SLRX), the Return on Equity (ROE) stands at -139.55%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -100.54%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Salarius Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -117.81%, showcasing its effectiveness in deploying capital for earnings.
Salarius Pharmaceuticals Inc (SLRX) Efficiency & Liquidity Metrics
Based on Salarius Pharmaceuticals Inc’s (SLRX) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Salarius Pharmaceuticals Inc (SLRX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Salarius Pharmaceuticals Inc. (SLRX) effectively leverages its workforce, generating an average of -$2500000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.79% and a Quick Ratio of 2.79%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Salarius Pharmaceuticals Inc [SLRX]
With the latest financial reports released by the company, Salarius Pharmaceuticals Inc posted -11.4/share EPS, while the average EPS was predicted by analysts to be reported at -804/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 792.6. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLRX.
Insider trade positions for Salarius Pharmaceuticals Inc [SLRX]
There are presently around $5.25%, or 5.27%% of SLRX stock, in the hands of institutional investors.
